The Effect of Antivascular Endothelial Growth Factor Therapy on the Development of Neovascular Glaucoma After Central Retinal Vein Occlusion: a Retrospective Analysis

Overview

Journal J Ophthalmol

Publisher Wiley

Specialty Ophthalmology

Date 2014 May 7

PMID 24800060

Citations 6

Authors

Christina L Ryu

Adrian Elfersy

Uday Desai

Thomas Hessburg

Paul Edwards

Hua Gao

Affiliations

Soon will be listed here.

Abstract

Purpose. Ischemic central retinal vein occlusion (CRVO) eyes are at high risk of developing neovascular glaucoma (NVG). Our purpose is to investigate the effect of anti-VEGF therapy for macular edema after CRVO on the development of neovascular glaucoma (NVG) in ischemic CRVO eyes. Methods. This is a retrospective case series of 44 eyes from 44 patients with CRVO treated with anti-VEGF therapy for macular edema. The primary outcome was the development of NVG. Results. Of the 44 eyes, 14 eyes had ischemic CRVO, and 30 eyes had nonischemic CRVO. Nonischemic eyes received a mean of 8.4 anti-VEGF doses, over mean follow-up of 24 months. One nonischemic eye (3.3%) developed NVD but not NVG. The 14 ischemic eyes received a mean of 5.6 anti-VEGF doses, with mean follow-up of 23 months. Of these 14 ischemic eyes, two eyes (14%) developed iris neovascularization and 3 eyes (21%) developed posterior neovascularization. Three of these 5 eyes with neovascularization progressed to NVG, at 19.7 months after symptom onset, on average. Conclusion. Anti-VEGF therapy for macular edema may delay, but does not prevent, the development of ocular NV in ischemic CRVO. Significant risk of NVG still exists for ischemic CRVO eyes.

Citing Articles

Quadrant Asymmetry in Optical Coherence Tomography Angiography Metrics in Ischemic Versus Non-Ischemic Central Retinal Vein Occlusion Eyes.

Jung J, Chan X, Lim S, Lee S, Rofagha S, Hoang Q Transl Vis Sci Technol. 2023; 12(3):30.

PMID: 36988945 PMC: 10064914. DOI: 10.1167/tvst.12.3.30.

Review: The Development of Risk Factors and Cytokines in Retinal Vein Occlusion.

Tang Y, Cheng Y, Wang S, Wang Y, Liu P, Wu H Front Med (Lausanne). 2022; 9:910600.

PMID: 35783660 PMC: 9240302. DOI: 10.3389/fmed.2022.910600.

Central retinal thickness changes and risk of neovascular glaucoma after intravitreal bevacizumab injection in patients with central retinal vein occlusion.

Lee Y, Kim Y Sci Rep. 2022; 12(1):2051.

PMID: 35136171 PMC: 8826410. DOI: 10.1038/s41598-022-06121-x.

Results from the Population-Based Gutenberg Health Study Revealing Four Altered Autoantibodies in Retinal Vein Occlusion Patients.

Bell K, Beutgen V, Nickels S, Lorenz K, Scheller Y, Elbaz H J Ophthalmol. 2020; 2020:8386160.

PMID: 32802490 PMC: 7411451. DOI: 10.1155/2020/8386160.

The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy.

Pozarowska D, Pozarowski P Cent Eur J Immunol. 2016; 41(3):311-316.

PMID: 27833450 PMC: 5099389. DOI: 10.5114/ceji.2016.63132.

References

Brown D, Heier J, Clark W, Boyer D, Vitti R, Berliner A . Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2012; 155(3):429-437.e7. DOI: 10.1016/j.ajo.2012.09.026. View

Hayreh S, Klugman M, Beri M, Kimura A, Podhajsky P . Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase. Graefes Arch Clin Exp Ophthalmol. 1990; 228(3):201-17. DOI: 10.1007/BF00920022. View

Beutel J, Ziemssen F, Luke M, Partsch M, Bartz-Schmidt K, Gelisken F . Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results. Int Ophthalmol. 2008; 30(1):15-22. DOI: 10.1007/s10792-008-9282-7. View

Hayreh S, Zimmerman M . Ocular neovascularization associated with central and hemicentral retinal vein occlusion. Retina. 2012; 32(8):1553-65. DOI: 10.1097/IAE.0b013e318246912c. View

Campochiaro P, Heier J, Feiner L, Gray S, Saroj N, Rundle A . Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117(6):1102-1112.e1. DOI: 10.1016/j.ophtha.2010.02.021. View

Aiello L, Avery R, Arrigg P, Keyt B, Jampel H, Shah S . Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331(22):1480-7. DOI: 10.1056/NEJM199412013312203. View

Epstein D, Algvere P, von Wendt G, Seregard S, Kvanta A . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology. 2012; 119(6):1184-9. DOI: 10.1016/j.ophtha.2012.01.022. View

McIntosh R, Rogers S, Lim L, Cheung N, Wang J, Mitchell P . Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010; 117(6):1113-1123.e15. DOI: 10.1016/j.ophtha.2010.01.060. View

Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F . Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008; 115(9):1571-80, 1580.e1-3. DOI: 10.1016/j.ophtha.2008.02.026. View

10.

Brown D, Campochiaro P, Singh R, Li Z, Gray S, Saroj N . Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117(6):1124-1133.e1. DOI: 10.1016/j.ophtha.2010.02.022. View

11.

Noma H, Funatsu H, Mimura T . Changes of inflammatory factors after intravitreal triamcinolone acetonide for macular edema with central retinal vein occlusion. J Ocul Pharmacol Ther. 2012; 29(3):363-5. DOI: 10.1089/jop.2011.0222. View

12.

Sohn H, Han D, Lee D, Nam D . Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion. Acta Ophthalmol. 2013; 92(3):e217-24. DOI: 10.1111/aos.12219. View

13.

Murdoch I, Rosen P, Shilling J . Neovascular response in ischaemic central retinal vein occlusion after panretinal photocoagulation. Br J Ophthalmol. 1991; 75(8):459-61. PMC: 1042430. DOI: 10.1136/bjo.75.8.459. View

14.

Chan C, Ip M, VanVeldhuisen P, Oden N, Scott I, Tolentino M . SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion. Ophthalmology. 2011; 118(7):1364-72. PMC: 3129404. DOI: 10.1016/j.ophtha.2010.11.020. View

15.

Hayreh S, Rojas P, Podhajsky P, Montague P, Woolson R . Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology. 1983; 90(5):488-506. DOI: 10.1016/s0161-6420(83)34542-5. View

16.

. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol. 1997; 115(4):486-91. DOI: 10.1001/archopht.1997.01100150488006. View

17.

Cugati S, Wang J, Rochtchina E, Mitchell P . Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol. 2006; 124(5):726-32. DOI: 10.1001/archopht.124.5.726. View

18.

Hayreh S, Podhajsky P, Zimmerman M . Natural history of visual outcome in central retinal vein occlusion. Ophthalmology. 2010; 118(1):119-133.e1-2. PMC: 2989417. DOI: 10.1016/j.ophtha.2010.04.019. View

19.

Campochiaro P, Brown D, Awh C, Lee S, Gray S, Saroj N . Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011; 118(10):2041-9. DOI: 10.1016/j.ophtha.2011.02.038. View

20.

Grover S, Murthy R, Brar V, Chalam K . Comparison of retinal thickness in normal eyes using Stratus and Spectralis optical coherence tomography. Invest Ophthalmol Vis Sci. 2009; 51(5):2644-7. DOI: 10.1167/iovs.09-4774. View